As we approach the imminent release of the ICH E9 Addendum, Estimands is moving from a concept to reality with some Regulators already asking “What is your Estimand?” But where do you start when defining your Estimand? What is the Estimand of interest and to whom? What inter-current events could determine your Estimand and thus your analysis methodology? The PSI Scientific Committee have put together this one day meeting to provide Statisticians with real world examples of how Estimands have been defined. Presenters will give their insight into discussions with colleagues, working groups and regulators and there will be plenty of opportunity to ask your questions on defining an Estimand.

Estimands and Sensitivity Analyses: What’s in the new ICH E9 Addendum? – Chrissie Fletcher (Amgen)

The Estimands Concept - Experiences when Introducing the Concept in a Global Development Organization – Michael Kunz (Bayer)

Disentangling Estimands and the Intention-to-Treat Principle - Ann-Kristin Leuchs (BfARM) (TBC)

Use of clear estimands - beyond hypothesis testing—Yolanda Barbachano (MHRA)

A Journey Towards Estimand Specification in Pain: Motivation and Challenges – Francesca Callegari (Novartis)

Estimands in Chronic Symptomatic Diseases – Martin Jenkins (AstraZeneca)

Estimands Examples in Neuroscience - TBC on behalf of the EFSPI working group

+ Others TBC

Register at: http://psiweb.org/events/psi-events

Please contact the PSI secretariat on psi@mci-group.com if you have any queries.